Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Pharmacology and Experimental Therapeutics|January 27, 2009
A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal modelsGabriel Mbalaviele, Cynthia D Sommers, Sheri L Bonar, et al.
Plos One|May 5, 2012
Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in miceSheri L Bonar, Susannah D Brydges, James L Mueller, et al.
The Journal of Biological Chemistry|February 20, 2010
Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptidesEric T Baima, Julia A Guzova, Sumathy Mathialagan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 6, 2014
NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanismsChao Qu, Sheri L Bonar, Cynthia L Hickman-Brecks, et al.
The Journal of Experimental Medicine|March 18, 2018
Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signalsChun Wang, Susan Hockerman, E Jon Jacobsen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 30, 2009
Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammationCynthia D Sommers, Janice M Thompson, Julia A Guzova, et al.
Bioorganic & Medicinal Chemistry|January 18, 2011
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationshipJin Xie, Gennadiy I Poda, Yiding Hu, et al.
Bioorganic & Medicinal Chemistry|November 17, 2009
Aminopyridinecarboxamide-based inhibitors: Structure-activity relationshipDominique F Bonafoux, Sheri L Bonar, Michael Clare, et al.
Arthritis and Rheumatism|August 18, 2012
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL productionTimothy P LaBranche, Michael I Jesson, Zaher A Radi, et al.
Pageof 1